Come on mate. They are tardy and commercially inept (hence the low mkt cap to their potential), but trial results, they have a very good proven track record. Capital mkts in Australia are poor at forward pricing earnings on anything but the top 50 of the ASX200. On biotech they are spectacularly crap.
CYP's $50 million cap would be tenfold that if it were an American company with so many bright irons in the fire.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Capital mkts in Australia are poor at forward pricing earnings on anything but the top 50 of the ASX200. On biotech they are spectacularly crap.
(20min delay)